Cerebral Venous Sinus Thrombosis in a Young Female Misdiagnosed as Migraine Ending in a Permanent Vegetative State

A Case Report and Review of the Literature

Sana Alshurafa; Wadiah Alfilfil; Ayah Alshurafa; Khadijah Alhashim


J Med Case Reports. 2018;12(323) 

In This Article


CVT refers to any clot in the cerebral venous system. It is divided into deep, superficial, and dural venous sinuses.[1] CVST is a rare form of VTE. It represents approximately 0.5 to 3% of all types of strokes. Ninety percent of these strokes present with thrombosis in multiple locations, especially the sigmoid and transverse sinuses.[2] Its incidence has been reported previously to be between 2 and 5 per million per year. However, a recent study suggested a much higher incidence of 13 per million per year.[3] It can affect all ages, but is predominant in young people, with an estimated incidence of 3 to 4 per million in adults and 7 per million in children.[2] CVST is associated with sex predilection; 75% of all CVST patients are women, with a 3:1 ratio compared with men.[2]

CVT is associated with more than 100 reported risk factors, but a cause cannot be identified in up to 20 to 35% of cases.[1,2,4,5] These risk factors are either hereditary or acquired risk factors and often follow the classical Virchow triad of thrombogenesis, which includes hypercoagulability, vessel wall damage, and blood stasis.[2] For example, hereditary risk factors involve homocysteinemia, factor V Leiden homozygous mutation, G20210A prothrombin gene and methylenetetrahydrofolate reductase 677TT mutations, protein C and S and anti-thrombin III deficiency, and positive anticardiolipin or antiphospholipid antibodies. On the other hand, acquired risk factors include brain tumors, head trauma, central nervous system infections (bacterial meningitis, cerebral malaria), intracranial hypotension, extracerebral neoplasias, dural fistulas, hematological conditions, nephrotic syndrome, systemic vasculitis, medications (cisplatin, methotrexate, steroids, oral contraceptive (OC) pills), neurological surgery, lumbar puncture, pregnancy, and puerperium.[1,2,4–10] Regarding OCs, a case–control study demonstrated a significant association between the use of OCs and CVST, which was emphasized in a meta-analysis (pooled odds ratio 5.59). Unfortunately, contraceptive products that deliver a lower systemic estrogen dose such as NuvaRing have as much prothrombotic potential as combined OC.[2]

Thirty percent of CVST cases present acutely with symptoms appearing in less than 48 hours. In up to 50% of cases, symptoms present in a subacute pattern and develop between 48 hours and 30 days. The chronic form represents 20% of the cases, and the symptoms manifest over a period greater than 30 days and up to 6 months.[1,2,4–10]

The symptoms usually depend on whether good collaterals for blood drainage exist or not. In the presence of sufficient collaterals, the patient usually presents with intracranial hypertension symptoms while, if the collaterals are insufficient, the patient develops stroke and the disease manifests itself with ischemic symptoms that do not match the symptoms of a blockage in any arterial territories.[2] Headache is the most common complaint in CVST; it presents in almost 90% of patients. It is usually described as diffuse and progressive, but in a few patients may present as a thunderclap headache, suggesting subarachnoid hemorrhage.[2] Isolated headache without focal neurological findings or papilledema occurs in up to 25 to 40% of the patients.[2] Focal or generalized seizures are frequent, occurring in nearly 40% of patients.[2] Focal sensory and motor deficits are very common and sometimes suggest the location site.[2]

No certain blood test can diagnose CVT. The guidelines of the European Stroke Organization recommend using D-dimer before neuroimaging in patients with suspected CVT, except in those with an isolated headache and in case of prolonged duration of symptoms (more than 1 week).[7–11] The diagnosis of CVST is mainly radiological, either by CT scan or magnetic resonance imaging (MRI), or invasive angiography. Noncontrast CT scan can be used to diagnose CVST by looking for direct and indirect signs. The direct signs include visualizing the thrombus in the affected vessel, while the indirect signs involve damage to brain parenchyma from ischemia or vascular changes related to venous outflow disturbance.[2] The direct signs are the string sign and the dense triangle sign.[1,2,4–9] The string sign is found in 25% of CVST patients and is associated with the presence of cortical vein thrombosis in the noncontrast-enhancing CT. Slow blood flow can also produce the string sign, indicating it to be a nonspecific sign. The dense triangle sign can be seen during the first 2 weeks, and it has been reported in only 2% of CVST cases. It represents superior sagittal sinus (SSS) opacification from fresh coagulated blood. Mimicking occurs in patients with increased hematocrit or dehydration.[1,2,4–9]

After administering the contrast, the empty delta (or empty triangle) sign can be seen, and it has been reported in 10 to 35% of the cases. This is an intraluminal-filling defect surrounded by contrast in the posterior portion of the SSS. This sign can be mimicked by many conditions such as high splitting of the superior sagittal sinus, subdural hematoma, subarachnoid hemorrhage, epidural abscesses, and by the presence of fenestrations within the sinus.[2]

Indirect signs of CVST are much more commonly seen on CT scan than the direct signs. These are not specific, but they should draw attention to the search for thrombi.[2] These include the following: brain edema and swelling of the gyri, multiple infarcts,[9] hydrocephalus, and compression of the fourth ventricle, as well as venous infarction that appears as a low-attenuation lesion with or without subcortical hemorrhage.[2]

CT venography (CTV) can provide a rapid and reliable diagnosis of CVST with a reported sensitivity of 95% that make it the gold standard diagnostic study.[2] Some disadvantages of CTV are that it is time-consuming, the exposure to harmful radiations, contrast-related allergy, and nephrotoxicity. It is also operator-dependent for editing, which is needed to remove over-projecting bone of the intracranial vessels displayed by the angiogram. Because of these concerns, magnetic resonance venography (MRV) has been preferred to CTV. However, CTV is much more useful in subacute or chronic situations because of the varied density in thrombosed sinuses.[2]

Plain CT scan has a low sensitivity of 25 to 56%. While MRI can be normal in up to 30% of patients, MRV and CTV have an equivalent and higher sensitivity and specificity for the demonstration of the thrombosed segment.[2] The invasive modality of diagnosis is generally reserved when MRV or CTV results are inconclusive, or if an endovascular procedure is being considered.[2]

Therapeutic goals include relieving the venous drainage obstruction, treating high intracranial pressure and seizure, and managing the sequelae of CVST such as hydrocephalus, intracranial hemorrhage, and hemorrhagic stroke.

Adequate hydration should be initiated at the beginning[12] since dehydration is a hypercoagulative state. Treating seizures even after a single seizure is advisable since they increase the risk of anoxic damage. Ferro et al.[7] found that CVST patients with supratentorial lesions are at an increased risk of recurrent seizures within 2 weeks of diagnosis, supporting the use of antiepileptic drugs in these patients.[2,4] Heparin has been used to treat CVST since 1941. The evidence behind its safety and efficacy originated from the meta-analysis performed by Coutinho et al.,[13] which included the only two randomized studies with the minimum methodological standards. Heparin was associated with an absolute reduction in mortality of 13% (95% confidence interval 1–27%; p = 0.08) and a reduction in risk of death or dependence of 15% of patients, without causing an increase in new hemorrhagic lesions. Also, patients who did not receive anticoagulation therapy were observed to have a greater frequency of pulmonary embolism. More evidence to encourage the use of heparin comes from the observation that 39% of cases of CVST had intracerebral hemorrhage before treatment, and no worsening of prognosis was observed in 83% of patients treated with heparin.[2,4]

The guidelines of the European Federation of Neurological Societies (EFNS) recommend LMWH because of its practical advantages. However, unfractionated heparin may be preferred in cases where surgical intervention is anticipated because it is easily reversed with protamine sulfate.

Thrombolytic agents, given locally with endovascular jugular or femoral access, have been utilized since 1971 and have been increasingly used in the past few years. It seems that local fibrinolytic therapy restores blood flow more quickly and efficiently than heparin, but carries the risk of bleeding. Currently, there have been no clear indications for the use of local or systemic thrombolytic agents due to the lack of conclusive randomized trials supporting them.[1,2,4–12,14]

Mechanical techniques (that is, extracting the clot with waves) reduces the required thrombolytic dosage and therefore lowers the risk of intracranial hemorrhage. In general, thrombolytic therapy is used if clinical worsening continues despite anticoagulation.[1,2,4–12]

Intracranial hypertension can be treated with hypertonic saline or mannitol.[12] While obstructive hydrocephalus can be treated with neurosurgical evacuation of cerebrospinal fluid via ventriculostomy or, in persistent cases, ventriculoperitoneal shunt if necessary;[4] decompressive craniotomy is an option to treat intracranial hypertension and might be life-saving in patients who fail medical treatment. However, no randomized trials have been conducted yet to support this, and the evidence of its efficacy is derived from case series.[4]

The prognosis for CVST is variable. In the past, CVST was considered a postmortem diagnosis and was also regarded as almost always fatal. In early angiographic series, mortality ranged between 30 and 50%.[1,2,4–8] In recent series, widely variable proportions of case fatality ranging from 4 to 33% have been reported. In the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT), which is the largest prospective series of patients with CVT collected in different centers and countries, there was a reported case fatality rate of 4.3% of patients during the acute phase of CVT and 3.4% within 30 days from onset of symptoms. The most common cause of death was transtentorial herniation due to a unilateral hemorrhagic lesion or diffuse edema and bilateral lesions.[6] The main predictors of death within 30 days were seizure, mental status disturbances, coma (GCS 9), deep CVT, and right hemorrhage and posterior fossa lesions.[6]

The present case contains many pitfalls in the diagnosis and management leading to the following teaching points:

  • CVT can present with migraine-like headache alone and this is a high-risk feature for misdiagnosis, which can result in worsening of the illness.

  • Patients with deep CVT are at a high risk for clinical deterioration and preferably should be monitored in the ICU even if they are stable initially.

  • In the first 48 hours of admission, we suggest using unfractionated heparin instead of LMWH because of its short duration of action and the ease of reversal in case the patient's condition deteriorates and requires surgical intervention.

  • Endovascular thrombolysis or thrombectomy should be probably offered early to such rapidly deteriorating patients who do not respond to heparin.